Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

Wenqi Zhang; Chen Huang; Chen Huang; Ruixia Liu; Huichao Zhang; Weijing Li; Shaoning Yin; Lianjing Wang; Wei Liu; Lihong Liu; Lihong Liu

doi:10.3389/fimmu.2022.983934

Frontiers in Immunology (Oct 2022)

Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

Wenqi Zhang,
Chen Huang,
Chen Huang,
Ruixia Liu,
Huichao Zhang,
Weijing Li,
Shaoning Yin,
Lianjing Wang,
Wei Liu,
Lihong Liu,
Lihong Liu

Affiliations

Wenqi Zhang: Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Chen Huang: Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Chen Huang: Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang, China
Ruixia Liu: Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Huichao Zhang: Clinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Weijing Li: Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Shaoning Yin: Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Lianjing Wang: Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Wei Liu: Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Lihong Liu: Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Lihong Liu: Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang, China

DOI: https://doi.org/10.3389/fimmu.2022.983934
Journal volume & issue: Vol. 13

Abstract

Read online

Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS relapse who received low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy followed with Bruton’s tyrosine kinase inhibitor and programmed cell death protein 1 antibody after several lines of chemotherapy. However, limited reports on CAR-T cell therapy are applied for SCNSL, particularly those in combination with targeted agents. The current treatment combination for this case provides a new regimen for CNS relapse from DLBCL.Clinical Trial RegistrationClinicalTrials.gov number, NCT04666168.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords